ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathy.
Quan Dong NguyenJustis P EhlersDavid S BoyerXidong JinAndrea GianiMichael S Ehrlichnull nullPublished in: Eye (London, England) (2024)
BI 1467335 was well tolerated by patients with NPDR. There was a high variability in DRSS levels for individual patients over time, with no clear efficacy signal.
Keyphrases
- diabetic retinopathy
- placebo controlled
- end stage renal disease
- double blind
- clinical trial
- ejection fraction
- newly diagnosed
- study protocol
- optical coherence tomography
- chronic kidney disease
- open label
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- phase ii
- patient reported outcomes
- locally advanced